(Circulation. 1995;92:1801-1807.)
© 1995 American Heart Association, Inc.
Articles |
Effects of Increasing Maintenance Dose of Digoxin on Left Ventricular Function and Neurohormones in Patients With Chronic Heart Failure Treated With Diuretics and Angiotensin-Converting Enzyme Inhibitors
Presented in part at the American Heart Association 65th Scientific Sessions, November 16-19, 1992, New Orleans, La.
From the Divisions of Biostatistics and Cardiovascular Medicine, Henry Ford Heart and Vascular Institute, Detroit, Mich.
Correspondence to Mihai Gheorghiade, MD, Division of Cardiology, Northwestern University Medical School, Chicago, IL 60611.
Background Despite almost three centuries of use, the appropriate dosage of digitalis in patients with chronic heart failure and normal sinus rhythm has not been well studied.
Methods and Results We studied 22 patients with heart failure who were receiving constant daily doses of digoxin, diuretics, and angiotensin-converting enzyme (ACE) inhibitors. In 18 patients, the oral daily dose of digoxin was increased from a mean of 0.20±0.07 to 0.39±0.11 mg/day corresponding to an increase in the serum digoxin concentration from 0.67±0.22 to 1.22±0.35 ng/mL. Radionuclide and echocardiographic left ventricular ejection fraction; maximal treadmill time; heart failure score; serum concentrations of norepinephrine, aldosterone, atrial natriuretic factor, and antidiuretic hormone; and plasma renin activity were obtained before and after the increase in digoxin dose. Subsequently, 9 patients were randomized to receive digoxin and 9 to receive placebo and radionuclide ejection fraction measured after 12 weeks. With the higher dose of digoxin compared with the lower dose, there was a significant increase in radionuclide ejection fraction from 23.7±9.6% to 27.1±11.8% (P=.007). No significant changes were noted in heart failure score; exercise tolerance; serum concentrations of norepinephrine, atrial natriuretic factor, and antidiuretic hormone; and plasma renin activity. There was, however, an increase in serum aldosterone concentration. Twelve weeks after the patients were randomized to receive digoxin or placebo, there was a significant decrease in ejection fraction (from 29.4±10.4% to 23.7±8.9%) in the placebo group but not in patients who continued to receive digoxin (P=.002).
Conclusions The increase in maintenance digoxin dose, while maintaining serum concentrations within therapeutic range, resulted in a significant increase in left ventricular ejection fraction that was not associated with significant changes in heart failure score, exercise tolerance, and neurohumoral profile.
Key Words: hormones • digoxin • heart failure
This article has been cited by other articles:
 |
|
 |
|
  S. A. Hunt, W. T. Abraham, M. H. Chin, A. M. Feldman, G. S. Francis, T. G. Ganiats, M. Jessup, M. A. Konstam, D. M. Mancini, K. Michl, et al. 2009 Focused Update Incorporated Into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Developed in Collaboration With the International Society for Heart and Lung Transplantation J. Am. Coll. Cardiol., April 14, 2009; 53(15): e1 - e90. [Full Text] [PDF]
|
|
|
|
 |
|
 2005 WRITING COMMITTEE MEMBERS, S. A. Hunt, W. T. Abraham, M. H. Chin, A. M. Feldman, G. S. Francis, T. G. Ganiats, M. Jessup, M. A. Konstam, D. M. Mancini, et al. 2009 Focused Update Incorporated Into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: Developed in Collaboration With the International Society for Heart and Lung Transplantation Circulation, April 14, 2009; 119(14): e391 - e479. [Full Text] [PDF]
|
|
|
|
 |
|
 J. G.F. Cleland and D. Cullington Digoxin: Quo Vadis? Circ Heart Fail, March 1, 2009; 2(2): 81 - 85. [Full Text] [PDF]
|
|
|
|
 |
|
 J. L. Bauman, R. J. DiDomenico, M. Viana, and M. Fitch A Method of Determining the Dose of Digoxin for Heart Failure in the Modern Era Arch Intern Med, December 11, 2006; 166(22): 2539 - 2545. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Gheorghiade, D. J. van Veldhuisen, and W. S. Colucci Contemporary Use of Digoxin in the Management of Cardiovascular Disorders Circulation, May 30, 2006; 113(21): 2556 - 2564. [Full Text] [PDF]
|
|
|
|
 |
|
 A. Ahmed, M. W. Rich, T. E. Love, D. M. Lloyd-Jones, I. B. Aban, W. S. Colucci, K. F. Adams, and M. Gheorghiade Digoxin and reduction in mortality and hospitalization in heart failure: a comprehensive post hoc analysis of the DIG trial Eur. Heart J., January 2, 2006; 27(2): 178 - 186. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Gheorghiade, K. F. Adams Jr, and W. S. Colucci Digoxin in the Management of Cardiovascular Disorders Circulation, June 22, 2004; 109(24): 2959 - 2964. [Full Text] [PDF]
|
|
|
|
 |
|
 J M Dernellis and M P Panaretou Effects of digoxin on left atrial function in heart failure Heart, November 1, 2003; 89(11): 1308 - 1315. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. S. Rathore, J. P. Curtis, Y. Wang, M. R. Bristow, and H. M. Krumholz Association of Serum Digoxin Concentration and Outcomes in Patients With Heart Failure JAMA, February 19, 2003; 289(7): 871 - 878. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K Kjeldsen, A Norgaard, and M Gheorghiade Myocardial Na,K-ATPase: the molecular basis for the hemodynamic effect of digoxin therapy in congestive heart failure Cardiovasc Res, September 1, 2002; 55(4): 710 - 713. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Hayashi, M. Ohtani, T. Hiraishi, and Y. Kobayashi Postoperative synthetic human atrial natriuretic peptide infusion and oral spironolactone administration for a patient with giant atria and low plasma level of atrial natriuretic peptide J. Thorac. Cardiovasc. Surg., July 1, 2002; 124(1): 206 - 209. [Full Text] [PDF]
|
|
|
|
|
|
K. F. Adams Jr, M. Gheorghiade, B. F. Uretsky, J. H. Patterson, T. A. Schwartz, and J. B. Young Clinical benefits of low serum digoxin concentrations in heart failure J. Am. Coll. Cardiol., March 20, 2002; 39(6): 946 - 953. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. J. van Veldhuisen Low-dose digoxin in patients with heart failure: Less toxic and at least as effective? J. Am. Coll. Cardiol., March 20, 2002; 39(6): 954 - 956. [Full Text] [PDF]
|
|
|
|
 |
|
 W. L. Miller, K. R. Bailey, S. A. Weston, J. C. Burnett Jr., and R. J. Rodeheffer Hemodynamic and plasma atrial natriuretic peptide responses to acute digitalis therapy in patients with normal and impaired left ventricular function Eur J Heart Fail, January 1, 2002; 4(1): 63 - 72. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Manunta, P. Stella, R. Rivera, D. Ciurlino, D. Cusi, M. Ferrandi, J. M. Hamlyn, and G. Bianchi Left Ventricular Mass, Stroke Volume, and Ouabain-Like Factor in Essential Hypertension Hypertension, September 1, 1999; 34(3): 450 - 456. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. J. Hauptman and R. A. Kelly Digitalis Circulation, March 9, 1999; 99(9): 1265 - 1270. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. B. Young, M. Gheorghiade, B. F. Uretsky, J. H. Patterson, and K. F. Adams Jr. Superiority of "triple" drug therapy in heart failure: insights from the PROVED and RADIANCE trials J. Am. Coll. Cardiol., September 1, 1998; 32(3): 686 - 692. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. A. Umans, J. H. Cornel, C. Hic, J. Soto, C. Avendano, F. G. Vilchez, M. Bohm, S. Zoneraich, S. Yusuf, R. Gorlin, et al. Digoxin in Patients with Heart Failure N. Engl. J. Med., July 10, 1997; 337(2): 129 - 131. [Full Text]
|
|